Characteristics of ten included studies of ARB and risk of cancer.

ARB: angiotensin receptor blocker; ACEI: angiotensin-converting enzyme inhibitor; BB: beta-blocker; BMI: body mass index; CCB: calcium channel blocker; HR: hazard ratio; RR: rate ratio; NA: not available; NSAIDs: Non-steroidal anti-inflammatory drugs; UK, United Kingdom; USA: United States of America; DM: diabetes mellitus.
*All includes breast, colon, liver, lung, rectum, stomach, prostate and haematological.
Characteristics of ten included studies of ARB and risk of cancer.

ARB：血管紧张素Ⅱ受体拮抗剂（angiotensin receptor blocker, ARB）；ACEI：血管紧张素转换酶抑制剂（angiotensin-converting enzyme inhibitor, ACEI）；BB：β受体阻滞剂（beta-blocker, BB）；BMI：体质量指数（body mass index, BMI）；CCB：钙通道阻滞剂（calcium channel blocker, CCB）；HR：风险比（hazard ratio, HR）；RR：率比（rate ratio, RR）；NA：不可用（not available, NA）；NSAIDs：非甾体抗炎药（Non-steroidal anti-inflammatory drugs, NSAIDs）；UK：英国（United Kingdom, UK）；USA：美利坚合众国（United States of America, USA）；DM：糖尿病（diabetes mellitus, DM）。*纳入的癌种涵盖乳腺癌、结肠癌、肝癌、肺癌、直肠癌、胃癌、前列腺癌及血液系统恶性肿瘤。纳入的10项关于ARB与癌症风险的研究的特征。